Objective: To assess the quality of glaucoma referral letters and to report on the results of a survey of glaucoma specialists about referral letter content.Design: Cross-sectional study.Participants: A survey of 135 glaucoma specialists and audit of 200 consecutive referral letters to a tertiary glaucoma unit.Methods: An online questionnaire was sent to members of the Canadian and American Glaucoma Societies asking what they considered the most important data to be included in a glaucoma referral. Consecutive referral letters to a tertiary glaucoma unit were assessed for legibility and content on the basis of the survey results and information items in current (Read more...)
Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO
Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Uncategorized
BioLase, Auris to develop laser cataract-removal robot
BioLase and Auris Surgical Robotics have signed a letter of commitment to develop a cataract-removal robot, according to a news release. The robot will utilize BioLase’s patented WaterLase YSGG all-tissue atraumatic cutting technology mounted on a robotic operating system manufactured by Auris. The goal of the robot would be to improve the precision, safety and predictability of cataract-removal procedures
Uncategorized
Abbott reports quarterly net sales of $5.37 billion
Abbott reported third-quarter net sales of $5.37 billion, up 2% from $5.27 billion in the same quarter a year ago, according to a news release.There was a negative impact on sales growth because of a sales disruption in the International Nutrition business, the release said.Quarterly sales for Abbott Medical Optics were $276 million; the increase was 11.7% on an operational sales basis and 7.3% on a reported sales basis.
Uncategorized
Study links genetic variants to poor outcomes after anti-VEGF treatment for AMD
Variants in genes connected to age-related macular degeneration were associated with poor visual outcomes after treatment with ranibizumab or bevacizumab, according to a study.The prospective study included 224 patients with neovascular AMD who underwent intravitreal injections of 0.5 mg Lucentis (ranibizumab, Genentech) or 1.25 mg Avastin (bevacizumab, Genentech).Patients underwent three monthly injections and as-needed injections for an additional 9 months; patients received an average of 6.4 injections.
Software enables yoga for the blind
In a typical yoga class, students watch an instructor to learn how to properly hold a position. But for people who are blind or can’t see well, it can be frustrating to participate in these types of exercises…